| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 20/12/2024 | 13:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 20/12/2024 | 12:50 | GlobeNewswire Inc. | Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection) | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 17/12/2024 | 12:50 | GlobeNewswire Inc. | Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 12/12/2024 | 22:27 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 09/12/2024 | 23:11 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 03/12/2024 | 12:50 | GlobeNewswire Inc. | Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 25/11/2024 | 12:50 | GlobeNewswire Inc. | Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension) | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 12/11/2024 | 22:25 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 12/11/2024 | 22:01 | GlobeNewswire Inc. | Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 07/11/2024 | 13:00 | GlobeNewswire Inc. | Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution) | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 06/11/2024 | 22:30 | GlobeNewswire Inc. | Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 04/10/2024 | 22:19 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 03/10/2024 | 12:30 | GlobeNewswire Inc. | Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 22/08/2024 | 22:30 | GlobeNewswire Inc. | Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 08/08/2024 | 22:01 | GlobeNewswire Inc. | Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 02/08/2024 | 22:16 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 30/07/2024 | 23:30 | GlobeNewswire Inc. | Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 15/07/2024 | 22:05 | GlobeNewswire Inc. | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution) | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 09/05/2024 | 22:01 | GlobeNewswire Inc. | Eton Pharmaceuticals Reports First Quarter 2024 Financial Results | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 01/05/2024 | 22:05 | GlobeNewswire Inc. | Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 30/04/2024 | 13:00 | GlobeNewswire Inc. | Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution) | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 29/04/2024 | 22:30 | GlobeNewswire Inc. | Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 22/03/2024 | 07:00 | GlobeNewswire Inc. | Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 14/03/2024 | 21:01 | GlobeNewswire Inc. | Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 29/02/2024 | 22:01 | GlobeNewswire Inc. | Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024 | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 21/02/2024 | 12:50 | GlobeNewswire Inc. | Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 02/02/2024 | 12:50 | GlobeNewswire Inc. | Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 09/11/2023 | 22:01 | GlobeNewswire Inc. | Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 30/10/2023 | 11:50 | GlobeNewswire Inc. | Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 | NASDAQ:ETON | Eton Pharmaceuticals Inc |
| 18/10/2023 | 14:00 | PR Newswire (US) | SWK Holdings Highlights Recent Achievements and Provides Portfolio Update | NASDAQ:ETON | Eton Pharmaceuticals Inc |